Search

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Maximising the ocular surface prior to cataract surgery: The old and the new modalities of treatment

Cataract surgery is among the most commonly performed surgical procedures worldwide. Over time, it has evolved from a lens-extraction procedure into a refractive intervention that demands meticulous perioperative planning and precision to achieve optimal outcomes. Optimisation of the ocular surface...

Emerging developments in dry eye

An estimated 344 million people worldwide suffer from dry eye [1]. This chronic syndrome is characterised by a vicious cycle of tear film hyperosmolarity, tear instability and corneal stress, leading to increased friction, inflammation, ocular surface damage and decreased visual...

Optimising the ocular surface by managing meibomian gland dysfunction

Meibomian gland dysfunction (MGD) is ubiquitous. Ocular surface inflammation and irritation are prevalent in most ophthalmology clinics: corneal, cataract, glaucoma, oculoplastic, paediatric, vitreo-retinal, medical retina and refractive surgery. These patients also represent roughly one third of those attending for emergency...

Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting

The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...

COVID-19 and the eye: a review of ocular involvement and protective strategies

A lot of attention has been placed on the use of face coverings to limit COVID-19 transmission, but there has been less focus on ocular involvement and ocular protection strategies. The author reviews the literature and discusses possible solutions. The...

The science of glaucoma management: highlights of the 2020 Moorfields International Glaucoma Symposium

Held earlier this year, the 12th annual Moorfields International Glaucoma Symposium provided a forum for advanced clinical and scientific exchange in glaucoma management. The authors describe the key presentation themes and debates, highlighting specific topics of interest to glaucoma specialists....

Personalising the management of dry eye disease: TFOS DEWS III updates evidence-based recommendations

Dry eye disease (DED) is a heterogenous condition that arises from various aetiologic factors and leads to tear film instability, ocular surface damage and neurosensory changes. Symptoms of DED include ocular dryness, burning, itching, pain and visual impairment. An evidence-based...